Last reviewed · How we verify

Advair Diskus — Competitive Intelligence Brief

Advair Diskus (Advair Diskus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid / long-acting beta-2 agonist (ICS/LABA). Area: Respiratory / Pulmonology.

marketed Combination inhaled corticosteroid / long-acting beta-2 agonist (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Advair Diskus (Advair Diskus) — Johns Hopkins University. Advair Diskus combines a long-acting beta-2 agonist and an inhaled corticosteroid to relax airway muscles and reduce airway inflammation in asthma and COPD.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Advair Diskus TARGET Advair Diskus Johns Hopkins University marketed Combination inhaled corticosteroid / long-acting beta-2 agonist (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid / long-acting beta-2 agonist (ICS/LABA) class)

  1. Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Advair Diskus — Competitive Intelligence Brief. https://druglandscape.com/ci/advair-diskus. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: